Expression of interleukin-33 is correlated with poor prognosis of patients with squamous cell carcinoma of the tongue

Auris Nasus Larynx

Volumn 41, Issue 6, 2014, Pages 552-557

  Ishikawa, Kazuya ^a   Yagi Nakanishi, Sayaka ^a   Nakanishi, Yosuke ^a   Kondo, Satoru ^a   Tsuji, Akira ^a   Endo, Kazuhira ^a   Wakisaka, Naohiro ^a   Murono, Shigeyuki ^a   Yoshizaki, Tomokazu ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Inflammation; Interleukin 33; Malignant potential; Mast cell; ST2; Tongue squamous cell carcinoma

Indexed keywords

ACTIVATION INDUCED CYTIDINE DEAMINASE; INTERLEUKIN 33; ONCOPROTEIN; PROTEIN ST2; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; IL1RL1 PROTEIN, HUMAN; IL33 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CAPILLARY DENSITY; CELL MATURATION; CELL SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL RATE; TONGUE CARCINOMA; TUMOR MICROENVIRONMENT; HEAD AND NECK TUMOR; IMMUNOLOGY; MAST CELL; METABOLISM; MICROVASCULATURE; MIDDLE AGED; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TONGUE TUMOR; TUMOR RECURRENCE; VASCULARIZATION;

CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKINS; MALE; MAST CELLS; MICROVESSELS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTORS, CELL SURFACE; TONGUE NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84922319724     PISSN: 03858146     EISSN: 18791476     Source Type: Journal    
DOI: 10.1016/j.anl.2014.08.007     Document Type: Article

References (35)

1. Yoshizaki T., Maruyama Y., Sato H., Furukawa M. Expression of tissue inhibitor of matrix metalloproteinase-2 correlates with activation of matrix metalloproteinase-2 and predicts poor prognosis in tongue squamous cell carcinoma. Int J Cancer 2001, 95:44-50.
2. Shimizu Y., Kondo S., Shirai A., Furukawa M., Yoshizaki T. A single nucleotide polymorphism in the matrix metalloproteinase-1 and interleukin-8 gene promoter predicts poor prognosis in tongue cancer. Auris Nasus Larynx 2008, 35:381-389.
3. Endo K., Takino T., Miyamori H., Kinsen H., Yoshizaki T., Furukawa M., et al. Cleavage of syndecan-1 by membrane type matrix metalloproteinase-1 stimulates cell migration. J Biol Chem 2003, 278:40764-40770.
4. Hirota K., Wakisaka N., Sawada-Kitamura S., Kondo S., Endo K., Tsuji A., et al. Lymphangiogenesis in regional lymph nodes predicts nodal recurrence in pathological N0 squamous cell carcinoma of the tongue. Histopathology 2012, 61:1065-1071.
5. Piemonte E.D., Lazos J.P., Brunotto M. Relationship between chronic trauma of the oral mucosa, oral potentially malignant disorders and oral cancer. J Oral Pathol Med 2010, 39:513-517.
6. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
7. Schmitz J., Owyang A., Oldham E., Song Y., Murphy E., McClanahan T.K., et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005, 23:479-490.
8. Liew F.Y., Pitman N.I., Mclnnes I.B. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol 2010, 10:103-110.
9. Allakhverdi Z., Smith D.E., Comeau M.R., Delespesse G. Cutting edge: The ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J Immunol 2007, 179:2051-2054.
10. Cherry W.B., Yoon J., Bartemes K.R., Iijima K., Kita H. A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J Allergy Clin Immunol 2008, 121:1484-1490.
11. Kamekura R., Kojima T., Takano K., Go M., Sawada N., Himi T. The role of IL-33 and its receptor ST2 in human nasal epithelium with allergic rhinitis. Clin Exp Allergy 2012, 42:218-228.
12. Aoki S., Hayakawa M., Ozaki H., Takezako N., Obata H., Ibaraki N., et al. ST2 gene expression is proliferation-dependent and its ligand, IL-33, induces inflammatory reaction in endothelial cells. Mol Cell Biochem 2010, 335:75-81.
13. Lamkanfi M., Dixit V.M. IL-33 raises alarm. Immunity 2009, 31:5-7.
14. Lüthi A.U., Cullen S.P., McNeela E.A., Duriez P.J., Afonina I.S., Sheridan C., et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 2009, 31:84-98.
15. Hong S.N., Jo S., Jang J.H., Choi J., Kim S., Ahn S.Y., et al. Clinical characteristics and the expression profiles of inflammatory cytokines/cytokine regulatory factors in asymptomatic patients with nodular gastritis. Dig Dis Sci 2012, 57:1486-1495.
16. Marvie P., Lisbonne M., L'helgoualc'h A., Rauch M., Turlin B., Preisser L., et al. Interleukin-33 overexpression is associated with liver fibrosis in mice and human. J Cell Mol Med 2010, 14:1726-1739.
17. Pastorelli L., Garg R.R., Hoang S.B., Spina L., Mattioli B., Scarpa M., et al. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci U S A 2010, 107:8017-8022.
18. Sun P., Ben Q., Tu S., Dong W., Qi X., Wu Y. Serum interleukin-33 levels in patients with gastric cancer. Dig Dis Sci 2011, 56:3596-3601.
19. Schmieder A., Multhoff G., Radons J. Interleukin-33 acts as a pro-inflammatory cytokine and modulates its receptor gene expression in highly metastatic human pancreatic carcinoma cells. Cytokine 2012, 60:514-521.
20. Miller A.M. Role of IL-33 in inflammation and disease. J Inflamm (Lond) 2011, 8:22.
21. Ribatti D., Crivellato E., Roccaro A.M., Ria R., Vacca A. Mast cell contribution to angiogenesis related to tumour progression. Clin Exp Allergy 2004, 34:1660-1664.
22. Crivellato E., Nico B., Ribatti D. Mast cell contribution to tumor angiogenesis: a clinical approach. Eur Cytokine Netw 2009, 20:197-206.
23. Iikura M., Suto H., Kajiwara N., Oboki K., Ohno T., Okayama Y., et al. IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab Invest 2007, 87:971-978.
24. Nakanishi Y., Kondo S., Wakisaka N., Tsuji A., Endo K., Murono S., et al. Role of activation-induced cytidine deaminase in the development of oral squamous cell carcinoma. PLoS One 2013, 8:e62066.
25. Qiu C., Li Y., Li M., Li M., Liu X., McSharry C., et al. Anti-interleukin-33 inhibits cigarette smoke-induced lung inflammation in mice. Immunology 2013, 138:76-82.
26. TNM classification of malignant tumors 1997, 4-8. Wiley-Liss, New York, USA. 5th ed. L.H. Sobin, C. Wittekind (Eds.).
27. Weidner N., Semple J.P., Welch W.R., Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991, 324:1-8.
28. Milovanovic M., Volarevic V., Radosavljevic G., Jovanovic I., Pejnovic N., Arsenijevic N., et al. IL-33/ST2 axis in inflammation and immunopathology. Immunol Res 2012, 52:89-99.
29. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441:431-436.
30. Hallett M.A., Venmar K.T., Fingleton B. Cytokine stimulation of epithelial cancer cells: the similar and divergent functions of IL-4 and IL-13. Cancer Res 2012, 72:6338-6343.
31. Townsend M.J., Fallon P.G., Matthews D.J., Jollin H.E., McKenzie A.N. T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. J Exp Med 2000, 191:1069-1076.
32. Jovanovic I., Radosavljevic G., Mitrovic M., Juranic V.L., McKenzie A.N., Arsenijevic N., et al. ST2 deletion enhances innate and acquired immunity to murine mammary carcinoma. Eur J immunol 2011, 41:1902-1912.
33. Choi Y.S., Choi H.J., Min J.K., Pyun B.J., Maeng Y.S., Park H., et al. Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production. Blood 2009, 114:3117-3126.
34. Alkhabuli J.O. Significance of neo-angiogenesis and immune-surveillance cells in squamous cell carcinoma of the tongue. Libyan J Med 2007, 2:30-39.
35. Michailidou E.Z., Markopoulos A.K., Antoniades D.Z.V.E.G.F. expression from human dysplastic or malignant oral epithelium may be related to mast cell density and the subsequent angiogenetic phenomena. Int J Oral Maxillofac Surg 2012, 41:1467-1473.